Sagent Pharma Cash Flow - Annual (NASDAQ:SGNT)

Add to My Stocks
$21.76 $0.03 (0.14%) SGNT stock closing price Aug 29, 2016 (Closing)

The Sagent Pharma cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. The profit-loss statement shows Sagent Pharma profits, the balance sheet shows Sagent Pharma debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. Sagent Pharma had cash and cash equivalents of $55.63M at beginning of the year and $28.96M at year end for 2015. Sagent Pharma cash flow analysis tells whether or not the company has enough cash for its day to day activities, and for investing for future growth. SGNT decrease in investments stood at a value of $-21.99M for the latest year 2015.

View details of Sagent Pharma cash flows for latest & last 10 financial years
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2015201420132012201120102009
Net Income Cash Flow
-21.88M39.88M29.59M-16.81M-26.42M-24.49M-30.53M
Depreciation Depletion Amortization Cash-Flow13.68M9.52M7.07M5.99M3.62M1.23M4.22M
Net Increase (Decrease) in Assets Liabilities-18.83M-8.71M-18.67M-3.53M-7.77M-18.58M
Cash From (used in) Discontinued Operations-------
Other Adjustments Net19.51M-26.23M4.16M9.37M5.91M3.24M2.1M
Net Cash from (used by) Operating Activities
-7.52M23.17M49.55M-20.12M-20.41M-27.79M-42.78M
Increase (Decrease) in Prop Plant And Equipment-6.71M-4.24M-1.1M-0.11M-0.32M-0.34M-0.06M
Acquisition Disposition of Subsidiaires-11.78M-86.46M-12.99M----
Increase (Decrease) in Investments-1.79M94.18M-78.48M35.97M-74.69M-5.19M-8.77M
Other Cash Inflow (Outflow) from Investment Activities-1.7M-4.4M-4.56M-3.22M-4.57M-1.73M-0.6M
Net Cash from (used by) Investment Activities
-21.99M-0.93M-97.15M32.63M-79.59M-7.27M-9.44M
Issuance (Purchase) of Equity Shares9.34M1.02M71.24M-101.55M45.61M30.05M
Issuance (Repayment) of Debt Securities-0.47M-10.42M-8.96M-12.27M12.27M--
Increase (Decrease) in Bank & Other Borrowings-5.18M1.15M--24.86M4.14M16.2M4.51M
Payment of Dividends & Other Cash Distributions-------
Other Cash from (used by) Financing Activities-0.18M-0.28M-0.02M-0.88M-0.12M-0.1M-0.27M
Net Cash from (used by) Financing Activities
3.5M-8.53M62.25M-37.02M117.84M61.71M34.29M
Effect of Exchange Rate Changes on Cash-0.65M-0.41M-0.01M----
Net Change in Cash & Cash Equivalents
-26.67M13.3M14.64M-24.51M17.82M26.64M-17.92M
Cash & Equivalents at Beginning of Year55.63M42.33M27.68M52.2M34.37M7.73M25.65M
Cash & Equivalents at Year End28.96M55.63M42.33M27.68M52.2M34.37M7.73M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Sagent Pharma stock price history provides insight into historical stock price fluctuations, and Sagent Pharma stock comparison chart enables peer comparison. Some of the key terms used in the statement of cash flows are:

  • Sagent Pharma has cash of $28.96M on hand. A healthy amount of cash on hand is necessary for any company. Cash has an opportunity cost associated with it, and too much cash in bank may mean that the firm has no or limited growth plans. Hence its important to track the Net Change in Cash and Cash Equivalents along with the Sagent Pharma stock price.
  • Cash Flow from operating activities: Sagent Pharma reported a negative operating cash flow of $-7.52M for 2015 and has seen a decrease from the previous year. Operating cash flow comes from main business activities. Investors look for positive cash flow from recurring operating activities.
  • Cash from investing stood at a negative value of $-21.99M for SGNT stock. A company with surplus cash usually thinks of re-investing it in the form of buying fixed assests, or purchasing plant/ machinery which will help grow the business further. By looking at cash flow from investment activities one can check where the company is putting its cash.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $3.5M for Sagent Pharma. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.